An interventional study of cTDCS and cTDCS in PARKINSON DISEASE (Disorder), sponsored by Université Libre de Bruxelles. Enrolling by invitation at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Université Libre de Bruxelles · Not applicable, Interventional, and Treatment
Background \& Rationale:
Treatment options for Parkinson's Disease (PD) often face challenges due to the variety of clinical subtypes, differing individual responses, and disease progression. Given its portability, affordability, safety, and ease of use, cerebellar transcranial direct current stimulation (ctDCS) presents as a promising option for home-based treatment with medical telemonitoring in the near future.
Study Procedures:
Participants are invited to complete questionnaires regarding quality of life, anxiety and depression, and symptoms related to their PD.
On the first day, they will be assessed using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III for motor impairment and the Cerebellar Cognitive Affective Syndrome scale (CCAS) for cognitive impairment. Participants will then undergo an additional 8 days of at-home cTDCS stimulation. On the 10th day, they will be reassessed using the MDS-UPDRS III and CCAS. One month later, they will complete again the questionnaires regarding quality of life, anxiety, depression, and symptoms related to their PD.
Objective:
Consequently, the primary goal is to investigate the effectiveness of ctDCS in addressing both motor and non-motor symptoms of PD
4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
This study's planned enrollment of 25 is below the median of 40 across 3,353 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Université Libre de Bruxelles is the lead sponsor of 45 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: cTDCS
Device: cTDCS
anodal cTDCS
cathodal cTDCS
MDS-UPDRS (Unit on a scale)
MDS-UPDRS Part III MDS-UPDRS Part I, II and IV
Time frame: day 1 to day 10 (MDS-UPDRS III) day 1 to day 40 (MDS-UPDRS Part I, II and IV)
CCAS (Unit on a scale)
CCAS scale
Time frame: day 1 and day 10
Feasibility and tolerability of ctDCS (Unit on a scale)
participant-reported outcomes regarding the ease of self-administration and the presence of side effects are collected through a dedicated questionnaire.
Time frame: from day 1 to day 10
Scale evaluation anxiety (Unit on a scale)
anxiety as evaluated by Generalized Anxiety Disorder-7 (GAD-7)
Time frame: day 1 and day 40
Scale evaluating depression (Unit on a scale)
depression as evaluated by Patient Health Questionnaire-9 (PHQ-9 )
Time frame: day 1 and day 40
Quality of life (Unit on a scale)
quality of life as evaluated by Parkinson's Disease Questionnaire-39 (PDQ-39)
Time frame: day 1 and day 40
Scale evaluation anxiety (Unit on a scale)
anxiety as evaluated by Beck Anxiety Inventory (BAI)
Time frame: day 1 and day 40
Scale evaluating depression (Unit on a scale)
depression as evaluated by Beck Depression Inventory (BDI)
Time frame: day 1 and day 40
Quality of life (Unit on a scale)
quality of life as evaluated by European Quality of Life 5 Dimensions (EQ-5D)
Time frame: day 1 and day 40
Plan to share: No — anonymous.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Université Libre de Bruxelles